Dacarbazine
- Generic Name
- Dacarbazine
- Drug Type
- Small Molecule
- Chemical Formula
- C6H10N6O
- CAS Number
- 4342-03-4
- Unique Ingredient Identifier
- 7GR28W0FJI
- Background
An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564). Dacarbazine with Oblimersen is in clinical trials for the treatment of malignant melanoma.
- Indication
For the treatment of metastatic malignant melanoma. In addition, dacarbazine is also indicated for Hodgkin's disease as a secondary-line therapy when used in combination with other antineoplastic agents.
- Associated Conditions
- Advanced Pancreatic Neuroendocrine Tumors (pNET), Advanced Soft Tissue Sarcoma, Hodgkin's Lymphoma, Metastatic Melanoma, Pheochromocytoma, Advanced Medullary thyroid cancer
Feasibility of Total Neoadjuvant Treatment With HYPErthermia in Patients With High-risk Extremity and Trunk Soft Tissue Sarcoma (TNT-HYPE)
- Conditions
- Sarcoma,Soft Tissue
- Interventions
- Other: HyperthermiaRadiation: RadiotherapyProcedure: Surgery
- First Posted Date
- 2025-02-19
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- Swiss Group for Clinical Cancer Research
- Target Recruit Count
- 24
- Registration Number
- NCT06835049
- Locations
- 🇨🇭
Kantonsspital Aarau, Aarau, Switzerland
🇨🇭Universitaetsspital Basel, Basel, Switzerland
🇨🇭EOC - Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland
A Study of Brentuximab Vedotin With Doxorubicin, Vinblastine and Dacarbazine in Adults With Hodgkin Lymphoma in India
- Conditions
- Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2025-02-18
- Last Posted Date
- 2025-02-18
- Lead Sponsor
- Takeda
- Target Recruit Count
- 124
- Registration Number
- NCT06831370
- Locations
- 🇮🇳
HCG City Cancer Centre, Vijayawada, Andhra Pradesh, India
🇮🇳Gauhati Medical college and Hospital, Guwahati, Assam, India
🇮🇳Unique Hospital Multispeciality and Research Institute, Surat, Gujarat, India
Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Hodgkin Lymphoma
- Conditions
- Advanced Hodgkin LymphomaClassic Hodgkin LymphomaLugano Classification Stage III Hodgkin Lymphoma AJCC v8Lugano Classification Stage IV Hodgkin Lymphoma AJCC v8
- Interventions
- Procedure: Biospecimen CollectionProcedure: Computed TomographyProcedure: EchocardiographyProcedure: Multigated Acquisition ScanProcedure: Positron Emission TomographyOther: Questionnaire
- First Posted Date
- 2024-12-20
- Last Posted Date
- 2025-03-10
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 125
- Registration Number
- NCT06745076
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
- Conditions
- Melanoma, Cutaneous Malignant
- Interventions
- First Posted Date
- 2024-12-19
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Immatics US, Inc.
- Target Recruit Count
- 360
- Registration Number
- NCT06743126
- Locations
- 🇺🇸
SCRI Oncology Partners, Nashville, Tennessee, United States
🇺🇸UCLA Hematology/Oncology, Los Angeles, California, United States
🇺🇸Honor Health Research Institute, Scottsdale, Arizona, United States
Brentuximab Vedotin for Newly Diagnosed CHL in Chinese CAYA Based on PET/CT Assessment
- Conditions
- Brentuximab VedotinYoung AdultPET ScanClassical Hodgkin LymphomaTreatmentChildAdolescentMetabolic ResponseSurvival
- Interventions
- Radiation: response-adapted radiationDrug: Bedamustine
- First Posted Date
- 2024-08-20
- Last Posted Date
- 2025-02-13
- Lead Sponsor
- Children's Cancer Group, China
- Target Recruit Count
- 96
- Registration Number
- NCT06563245
- Locations
- 🇨🇳
Shanghai Children's Medical Center, Shanghai, China
A Study of BV-AVD in People With Bulky Hodgkin Lymphoma
- Conditions
- Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2024-04-22
- Last Posted Date
- 2025-04-20
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 71
- Registration Number
- NCT06377566
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
🇺🇸Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown, New Jersey, United States
A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)
- Conditions
- Advanced or Metastatic NRAS-mutant Melanoma
- Interventions
- First Posted Date
- 2024-04-03
- Last Posted Date
- 2025-01-17
- Lead Sponsor
- Erasca, Inc.
- Target Recruit Count
- 470
- Registration Number
- NCT06346067
- Locations
- 🇺🇸
Mayo Clinic - Arizona, Phoenix, Arizona, United States
🇺🇸University of California, San Francisco, San Francisco, California, United States
🇺🇸The Melanoma and Skin Care Institute, Englewood, Colorado, United States
BV-AVD-R Treatment Children Hodgkin's Lymphoma
- Conditions
- Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2024-01-11
- Last Posted Date
- 2024-01-12
- Lead Sponsor
- Beijing Children's Hospital
- Target Recruit Count
- 44
- Registration Number
- NCT06201507
- Locations
- 🇨🇳
Duan Yanlong, Beijing, China
Pembrolizumab Followed by Chemotherapy for the Treatment of Patients With Classical Hodgkin Lymphoma
- Conditions
- Classic Hodgkin Lymphoma
- Interventions
- Procedure: BiopsyProcedure: Biospecimen CollectionProcedure: Computed TomographyProcedure: EchocardiographyProcedure: Multigated Acquisition ScanProcedure: Positron Emission Tomography
- First Posted Date
- 2023-12-11
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 30
- Registration Number
- NCT06164275
- Locations
- 🇺🇸
Stanford Cancer Center, Stanford, California, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
🇺🇸Northwestern Delnor IL258, Geneva, Illinois, United States
IDE196 (Darovasertib) in Combination with Crizotinib As First-line Therapy in Metastatic Uveal Melanoma
- Conditions
- Metastatic Uveal Melanoma
- Interventions
- First Posted Date
- 2023-08-14
- Last Posted Date
- 2025-03-28
- Lead Sponsor
- IDEAYA Biosciences
- Target Recruit Count
- 420
- Registration Number
- NCT05987332
- Locations
- 🇺🇸
Honor Health, Scottsdale, Arizona, United States
🇺🇸Moores Cancer Center, La Jolla, California, United States
🇺🇸UCLA Medical Center, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.